Tempo Therapeutics develops synthetic scaffolds for surgical reconstruction and wound healing.
Tempo Therapeutics develops synthetic biomaterials for surgical reconstruction and wound healing. Its MAP platform is designed to form a porous scaffold within irregular tissue spaces.
The company’s lead wound matrix has undergone a first-in-human study and has been submitted to the FDA through the De Novo pathway. Tempo is also planning research in more complex surgical wounds.
Loading profile details…
Biotechnology Engineering · Business involvement
As of 2026-11-08
Loading recent changes…
Brand marks identify the organization. Logo from the official website.
Co-founder
Co-founder and chief technology officer of Tempo Therapeutics.
View personal profile